{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,3,5]],"date-time":"2025-03-05T05:42:13Z","timestamp":1741153333791,"version":"3.38.0"},"reference-count":19,"publisher":"Oceanside Publications Inc.","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["allergy asthma proc"],"published-print":{"date-parts":[[2025,3,1]]},"abstract":"<jats:p><jats:bold>Background:<\/jats:bold> Studies on the impact of comorbidities on treatment responses in severe eosinophilic asthma (SEA) are limited. This study was a real-world investigation into how the presence or absence of nasal polyps (NP) and sensitivity to aeroallergens influence the outcomes\n of mepolizumab therapy.  <jats:bold>Methods:<\/jats:bold> In this retrospective study, data obtained from patients with SEA and who received at least 6 months of mepolizumab treatment were analyzed. The patients were initially divided into two groups based on the presence of NPs. Within these two\n groups, the patients were further categorized into subgroups according to the presence of aeroallergen sensitivity (AE). Asthma-related outcomes in the resulting four groups were evaluated both before mepolizumab treatment and during the follow-up period.  <jats:bold>Results:<\/jats:bold> Among\n the 36 patients with NPs, 14 (38.8%) had AE (NP+AE+), whereas 22 (61.2%) did not (NP+AE\u2010). Of the 35 patients without NPs, 17 (48.5%) had AE (NP\u2010AE+), and 18 (51.5%) did not (NP\u2010AE\u2010). The presence of NPs, independent of AE, was significantly associated with an increase\n in asthma exacerbations and oral corticosteroid (OCS) use before treatment (p &lt; 0.001). In the NP+AE+ group, the baseline Asthma Control Test (ACT) score was lower, and the number of hospitalizations was significantly higher (p &lt; 0.001). After mepolizumab treatment, all four groups showed\n significant reductions in asthma-related exacerbations, hospitalizations, and OCS use. Furthermore, ACT scores and pulmonary function test parameters significantly improved. There were limited differences in asthma improvements among the groups, with the NP+AE+ group showing a significant\n increase in ACT scores and a reduction in hospitalizations compared with the other groups (p &lt; 0.001).  <jats:bold>Conclusion:<\/jats:bold> Mepolizumab significantly reduced asthma exacerbations, hospitalizations, and OCS use in the patients with SEA with four different phenotypes. Analysis\n of these findings suggests that mepolizumab provides real-world benefits regardless of the presence or absence of NPs and AE.<\/jats:p>","DOI":"10.2500\/aap.2025.46.250003","type":"journal-article","created":{"date-parts":[[2025,2,27]],"date-time":"2025-02-27T04:31:02Z","timestamp":1740630662000},"page":"119-125","source":"Crossref","is-referenced-by-count":0,"title":["Influence of aeroallergen sensitization and nasal polyposis on mepolizumab response in eosinophilic severe asthma"],"prefix":"10.2500","volume":"46","author":[{"given":"Fatma Arzu","family":"Akkus","sequence":"first","affiliation":[{"name":"From the Department of Clinical Immunology and Allergy, Necmettin Erbakan University, Faculty of Medicine, Konya, Turkey;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fatih","family":"Colkesen","sequence":"additional","affiliation":[{"name":"From the Department of Clinical Immunology and Allergy, Necmettin Erbakan University, Faculty of Medicine, Konya, Turkey;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tugba","family":"Onalan","sequence":"additional","affiliation":[{"name":"From the Department of Clinical Immunology and Allergy, Necmettin Erbakan University, Faculty of Medicine, Konya, Turkey;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Recep","family":"Evcen","sequence":"additional","affiliation":[{"name":"Division of Clinical Immunology and Allergy, Department of Internal Medicine, Faculty of Medicine, Recep Tayyip Erdo\u011fan University, Rize, Turkey;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mehmet Emin","family":"Gerek","sequence":"additional","affiliation":[{"name":"From the Department of Clinical Immunology and Allergy, Necmettin Erbakan University, Faculty of Medicine, Konya, Turkey;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mehmet","family":"Kilinc","sequence":"additional","affiliation":[{"name":"Division of Clinical Immunology and Allergy, Department of Internal Medicine, Batman Training and Research Hospital, Batman, Turkey; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Filiz","family":"Sadi Aykan","sequence":"additional","affiliation":[{"name":"Division of Clinical Immunology and Allergy, Department of Internal Medicine, Batman Training and Research Hospital, Batman, Turkey; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sevket","family":"Arslan","sequence":"additional","affiliation":[{"name":"From the Department of Clinical Immunology and Allergy, Necmettin Erbakan University, Faculty of Medicine, Konya, Turkey;"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1355","reference":[{"key":"B1","doi-asserted-by":"crossref","first-page":"2382377","DOI":"10.1080\/07853890.2024.2382377","article-title":"Relationship between fraction of exhaled nitric oxide and peripheral eosinophilia in asthma","volume":"56","author":"Afriyie-Mensah","year":"2024","journal-title":"Ann Med"},{"key":"B2","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.3390\/jcm8091375","article-title":"Severe eosinophilic asthma","volume":"8","author":"Bakakos","year":"2019","journal-title":"J Clin Med"},{"key":"B3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jaci.2019.05.031","article-title":"Phenotypes and endotypes of adult asthma: moving toward precision medicine","volume":"144","author":"Kaur","year":"2019","journal-title":"J Allergy Clin Immunol"},{"key":"B4","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.anai.2015.10.027","article-title":"Overlap of atopic, eosinophilic, and TH2-high asthma phenotypes in a general population with current asthma","volume":"116","author":"Tran","year":"2016","journal-title":"Ann Allergy Asthma Immunol"},{"key":"B5","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.jaip.2019.11.008","article-title":"Allergic endotypes and phenotypes of asthma","volume":"8","author":"Akar-Ghibril","year":"2020","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B6","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1183\/13993003.00779-2015","article-title":"Clinical and inflammatory characteristics of the European U-BIOPRED adult severe asthma cohort","volume":"46","author":"Shaw","year":"2015","journal-title":"Eur Respir J"},{"key":"B7","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/j.chest.2019.10.053","article-title":"Characterization of severe asthma worldwide: data from the International Severe Asthma Registry","volume":"157","author":"Wang","year":"2020","journal-title":"Chest"},{"key":"B8","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/1465-9921-12-95","article-title":"Influence of degree of specific allergic sensitivity on severity of rhinitis and asthma in Chinese allergic patients","volume":"12","author":"Li","year":"2011","journal-title":"Respir Res"},{"key":"B9","doi-asserted-by":"crossref","first-page":"420","DOI":"10.4193\/Rhino09.095","article-title":"Comparative clinical and airway inflammatory features of asthmatics with or without polyps","volume":"48","author":"Bilodeau","year":"2010","journal-title":"Rhinology"},{"key":"B10","doi-asserted-by":"crossref","first-page":"e12049","DOI":"10.1002\/clt2.12049","article-title":"Real-life effectiveness of biological therapies on symptoms in severe asthma with comorbid CRSwNP","volume":"11","author":"M\u00fcmmler","year":"2021","journal-title":"Clin Transl Allergy"},{"key":"B11","doi-asserted-by":"crossref","first-page":"265","DOI":"10.2500\/aap.2023.44.230015","article-title":"Dupilumab efficacy in patients with chronic rhinosinusitis with nasal polyps with and without allergic rhinitis","volume":"44","author":"Peters","year":"2023","journal-title":"Allergy Asthma Proc"},{"key":"B12","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1016\/j.clinthera.2019.07.007","article-title":"Long-term safety and clinical benefit of mepolizumab in patients with the most severe eosinophilic asthma: the COSMEX Study","volume":"41","author":"Khurana","year":"2019","journal-title":"Clin Ther"},{"key":"B13","doi-asserted-by":"crossref","first-page":"675","DOI":"10.2147\/JAA.S298559","article-title":"Response to mepolizumab treatment in patients with severe eosinophilic asthma and atopic phenotypes","volume":"14","author":"Prazma","year":"2021","journal-title":"J Asthma Allergy"},{"key":"B14","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1183\/09031936.00220413","article-title":"The role of mepolizumab in atopic and nonatopic severe asthma with persistent eosinophilia","volume":"44","author":"Ortega","year":"2014","journal-title":"Eur Respir J"},{"key":"B15","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1186\/s12931-021-01767-z","article-title":"Impact of baseline clinical asthma characteristics on the response to mepolizumab: a post hoc meta-analysis of two phase III trials","volume":"22","author":"Lemiere","year":"2021","journal-title":"Respir Res"},{"key":"B16","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.anai.2021.05.021","article-title":"Real-world effectiveness of mepolizumab in patients with severe asthma and associated comorbidities","volume":"127","author":"Casale","year":"2021","journal-title":"Ann Allergy Asthma Immunol"},{"key":"B17","doi-asserted-by":"crossref","first-page":"341","DOI":"10.2500\/aap.2020.41.200043","article-title":"Impact of mepolizumab on exacerbations in severe asthma: results from a U.S. insurance claims data base","volume":"41","author":"Ortega","year":"2020","journal-title":"Allergy Asthma Proc"},{"journal-title":"Fontana, WI: Global Initiative for Asthma","article-title":"Global initiative for asthma report, 2022","year":"2022","key":"B18"},{"key":"B19","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1016\/j.jaci.2020.02.002","article-title":"Severe eosinophilic asthma with nasal polyposis: a phenotype for improved sinonasal and asthma outcomes with mepolizumab therapy","volume":"145","author":"Howarth","year":"2020","journal-title":"J Allergy Clin Immunol"}],"container-title":["Allergy and Asthma Proceedings"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ingentaconnect.com\/content\/ocean\/aap\/2025\/00000046\/00000002\/art00012","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,5]],"date-time":"2025-03-05T04:32:42Z","timestamp":1741149162000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ingentaconnect.com\/content\/10.2500\/aap.2025.46.250003"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,1]]},"references-count":19,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,3,1]]}},"alternative-id":["1088-5412(20250301)46:2L.119;1-"],"URL":"https:\/\/doi.org\/10.2500\/aap.2025.46.250003","relation":{},"ISSN":["1088-5412"],"issn-type":[{"type":"print","value":"1088-5412"}],"subject":[],"published":{"date-parts":[[2025,3,1]]}}}